APA (7th ed.) Citation

Han, T., Zhuo, M., Zheng, X., Wu, X., Jiao, F., Cui, J., . . . Xiao, X. (2025). Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: A single-arm, phase 2 clinical trial. Cellular Oncology (2211-3428), 48(6), 2073. https://doi.org/10.1007/s13402-025-01127-9

Chicago Style (17th ed.) Citation

Han, Ting, et al. "Surufatinib Plus Paclitaxel as Second-line Therapy for Advanced Gastric Cancer: A Single-arm, Phase 2 Clinical Trial." Cellular Oncology (2211-3428) 48, no. 6 (2025): 2073. https://doi.org/10.1007/s13402-025-01127-9.

MLA (9th ed.) Citation

Han, Ting, et al. "Surufatinib Plus Paclitaxel as Second-line Therapy for Advanced Gastric Cancer: A Single-arm, Phase 2 Clinical Trial." Cellular Oncology (2211-3428), vol. 48, no. 6, 2025, p. 2073, https://doi.org/10.1007/s13402-025-01127-9.